Clinical trials: Treatment Response
Acute Liver Failure, Fulminant Hepatic Failure
TReatment for ImmUne Mediated PathopHysiology
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure.
- Conditions
- Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury
- Trial name
- TRIUMPH (NCT04862221)
- Testing
- High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone
- Where
- 17 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Gastroparesis
Idiopathic Gastroparesis Registry Using a Predominant-Symptom Classification
The diagnosis of "gastroparesis" suggests that delayed gastric emptying is the underlying cause of symptoms, but this description fails to explain the variable presentation.
- Trial name
- NCT01173484
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Louisville
Crohn Disease
Personalising Anti-TNF Therapy in Crohns Disease (PANTS)
To develop a cost-effective, individualised anti-TNF treatment strategy for patients with Crohn's disease which maximizes benefit and minimises harm.
- Trial name
- PANTS (NCT03088449)
- Where
- United Kingdom
- Volunteers
- 1,750 people
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Cystic Fibrosis
Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients
The purpose of this study is to determine which biological marker, or association of biological markers, best predict clinical response of cystic fibrosis patients to CFTR modulators.
- Trial name
- BIO-CFTR (NCT02965326)
- Testing
- Nasal swab; rectal biopsy.
- Where
- France
- Volunteers
- 75 people
- Sponsor
- Hôpital Necker-Enfants Malades
Measles, Measles-Mumps-Rubella+Chickenpox Vaccine
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
This study is evaluating the immunogenicity and safety of intramuscular administration of the investigational MMRVNS vaccine compared to intramuscular administration of the MMRV (Merck's measles, mumps, rubella and varicella)…
- Trial name
- NCT07406360
- Testing
- MMRVNS, MMRV
- Where
- 17 sites in United States
- Volunteers
- 1,209 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Spinal Muscular Atrophy
Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies
In this observational study, researchers are looking at the effects of spinal muscular atrophy (SMA) drugs on the muscles and nerve cells in patients with SMA.
- Trial name
- NCT06532474
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- St. Jude Children's Research Hospital
Post Kala Azar Dermal Leishmaniasis
Ivermectin Repurposed for the Treatment of PKDL
Background (brief): 1. Burden: Post-Kala-Azar Dermal Leishmaniasis (PKDL) commonly follows visceral leishmaniasis (VL) caused by Leishmania donovani.
- Trial name
- NCT07286604
- Testing
- Ivermectin 6 MG Oral Tablet (2 tablets)
- Where
- Bangladesh
- Volunteers
- 10 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Systemic Lupus Erythematosus
Humanized LL2IGG to Treat Systemic Lupus Erythematosus
This study will examine the safety of a new genetically engineered antibody called hLL2 (epratuzumab) in patients with systemic lupus erythematosus (SLE).
- Trial name
- NCT00011908
- Testing
- hLL2 (Epratuzumab)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Ovarian Neoplasms
Prospective Identification and Validation of "BRCANess" Profile in Ovarian Epithelial Cancer
This is an observational prospective study. Patients diagnosed with advanced epithelial ovarian cancer (stage IC or higher) since 2008 will be asked to participate in this study by signing an informed consent.
- Trial name
- FindBRCANess (NCT02524808)
- Where
- 4 sites in Spain
- Volunteers
- 230 people
- Sponsor
- Fundación de investigación HM
Cystic Fibrosis
Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI
This is an observational study for children with Cystic Fibrosis (CF) who are eligible based on their CF gene type. One group will be called the treatment group because they have the gene type (homozygous F508del) that makes them…
- Trial name
- NCT02848560
- Testing
- Hyperpolarized Xenon
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Leptomeningeal Metastasis, Leptomeningeal Disease
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
The FORESEE Study is a multi-center, prospective clinical trial enrolling patients with Breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM).
- Conditions
- Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Breast Cancer
- Trial name
- FORESEE (NCT05414123)
- Testing
- CNSide
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Biocept, Inc.
Interactive Voice Response (IVR)
Treatment Follow-up Study
This study will assess the effectiveness of a medication safety monitoring method utilizing interactive voice response technology for youth recently prescribed anti-depressant medication.
- Trial name
- PhaST (NCT00995696)
- Testing
- PhaST IVR Calls
- Where
- 2 sites in United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Nationwide Children's Hospital
Hidradenitis Suppurativa
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- RECHARGE-2 (NCT06840392)
- Testing
- Remibrutinib Dose A, Remibrutinib Dose B
- Where
- 129 sites in United States, Argentina and 17 more
- Volunteers
- 565 people
- Sponsor
- Novartis Pharmaceuticals
Obsessive-Compulsive Disorder
Precision Brain Mapping to Predict and Track Response to Exposure and Response Prevention Therapy in Youth With Obsessive-Compulsive Disorder
The goal of this clinical trial is to learn whether brain scan results can help predict and track changes in obsessive-compulsive disorder, or OCD, symptoms in children and teens ages 10 to 17 who receive Exposure and Response…
- Trial name
- NCT07570108
- Testing
- Exposure and Response Prevention Therapy, Clinical Assessments, Research MRI Sessions
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Generalized Anxiety Disorder, Separation Anxiety Disorder
Treatment of Pediatric Anxiety Disorders by Predicting Treatment Response Through Biocellular Markers and Sleep
1 out of 8 children, adolescents, and young adults suffer from an anxiety disorder. Studies over the past decade show that selective serotonin-reuptake inhibitors (SSRIs), a class of medication that treats anxiety in adults, also…
- Conditions
- Generalized Anxiety Disorder, Separation Anxiety Disorder, Social Phobia
- Trial name
- NCT02189213
- Testing
- Sertraline
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Attention Deficit Hyperactivity Disorder
Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD)
Attention deficit hyperactivity disorder (ADHD) is the most common behavior disorder, with the prevalence of 3% to 6% in children and adolescents. The patients' academic achievements, professions and social livings are impaired.
- Trial name
- NCT01339286
- Testing
- atomoxetine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University
Pulmonary Arterial Hypertension
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
To evaluate the change from baseline in pulmonary vascular resistance (PVR), and other hemodynamic parameters, following the addition of ambrisentan to background phosphodiesterase type-5 inhibitor (PDE-5i) therapy in subjects…
- Trial name
- ATHENA-1 (NCT00617305)
- Testing
- Ambrisentan, Sildenafil, Tadalafil
- Where
- 30 sites in United States
- Volunteers
- 38 people
- Sponsor
- Gilead Sciences
Critical Laboratory Values, Drug Laboratory Interactions
Effect of an Automated Paging System on Response to Critical Laboratory Values
Patients in hospitals may develop serious problems that are detected by blood tests. It is very important for the physicians to be notified of these abnormal blood tests as soon as possible.
- Conditions
- Critical Laboratory Values, Drug Laboratory Interactions, Drug Drug Interactions
- Trial name
- NCT00469924
- Testing
- Real Time Clinical Alerting
- Where
- Canada
- Volunteers
- 271 people
- Sponsor
- Sunnybrook Health Sciences Centre
CLABSI - Central Line Associated Bloodstream Infection, CRBSI - Catheter Related Bloodstream Infection
Neonatal Catheter Lock for Infection Prevention
For newborns admitted to Neonatal Intensive Care Units (NICUs), one of the main risk factors for late-onset sepsis is the presence of a central venous catheter (CVC), which is often essential for the administration of medications…
- Conditions
- CLABSI - Central Line Associated Bloodstream Infection, CRBSI - Catheter Related Bloodstream Infection, Neonatal Sepsis, Late-Onset
- Trial name
- Neo-CLIP (NCT07585188)
- Testing
- Taurolidine 2% lock, Normal saline lock
- Where
- Italy
- Volunteers
- 576 people
- Sponsor
- University of Turin, Italy
Leukemia
Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045422
- Testing
- recombinant interferon alfa, imatinib mesylate
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center